Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PBTZ169 (Macozinone) in Healthy Volunteers
NCT03423030Phase 1Completed
- Sponsor
- Innovative Medicines for Tuberculosis Foundation
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of macozinone in Tuberculosis (TB) (4 arms), sponsored by Innovative Medicines for Tuberculosis Foundation. Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2017; status: completed.
02
Drugs
macozinone
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03423030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423030.